检验

订阅

MedSci主页 / 所有栏目 / 检验

CLIN CHEM LAB MED：RNA稳定剂对采血管分析前的稳定性影响

2019-11-17 MedSci MedSci原创

RNA稳定剂
关注

在临床前操作中，有效的血液稳定对于获得可靠和具有可比性的RNA分析数据至关重要。

在临床前操作中，有效的血液稳定对于获得可靠和具有可比性的RNA分析数据至关重要。带有RNA稳定剂的PAXgene（Qiagen，Becton Dickinson）和Tempus（Applied Biosystems，Life Technologies）血液采集管均避免了内源核酸酶对mRNA进行预分析降解，并避免了由于基因表达的无意上调或下调而导致的特定mRNA浓度的改变。

研究人员对7例供者的经PAXgene和Tempus保存的血液标本进行了16种不同的前分析条件的检测，包括采集后不同的混合方式、不同的填充体积和采集后24小时不同的运输温度条件。采用柱状法提取RNA，提取RNA的质量由光谱光度测量的量化评估，A260 / A280纯度比、RNA数量完整性(安捷伦生物分析仪)、对RNU-24和miR-16两个microRNA的定量实时聚合酶链反应、信使RNA质量指标（GAPDH基因的3′,5′区域）和基于相对IL8和EDEM3编码基因的表达水平的PBMC preanalytical分数。

研究发现，当按照PAXgene RNA和Tempus采血管按照制造商的说明使用时，输出的RNA质量属性没有统计学上或技术上的显著差异。但是，从Tempus收集管中提取的RNA的完整性对填充量和有效倒置比对存储温度更敏感，而从PAXgene收集管中提取的RNA的完整性对有效倒置和存储温度比对填充量更敏感。

不同RNA稳定剂的采血管对常见的分析前变化具有不同的鲁棒性。

原始出处：

Chiara Stellino，Gaël Hamot，Preanalytical robustness of blood collection tubes with RNA stabilizers

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900513, encodeId=588a1900513a3, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat May 30 01:16:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362054, encodeId=7fe01362054f6, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610129, encodeId=2c1d1610129f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-05-30 jiangfeng5067

    #稳定性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1900513, encodeId=588a1900513a3, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat May 30 01:16:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362054, encodeId=7fe01362054f6, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610129, encodeId=2c1d1610129f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 longqijun248

    #采血#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1900513, encodeId=588a1900513a3, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat May 30 01:16:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362054, encodeId=7fe01362054f6, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610129, encodeId=2c1d1610129f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:16:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 ms3994565386320060

    #Med#

    0